Oncternal Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Oncternal Therapeutics

04/05/2023 22:52

* Oncternal Therapeutics Inc  ONCT.OQ  reported a quarterly
adjusted loss of 20 cents​​ per share for the quarter ended in
March. The mean expectation of seven analysts for the quarter
was for a loss of 20 cents per share.
    * Revenue fell 72.8% to $203.00 thousand from a year ago;
analysts
expected $166.67 thousand. 
    * Oncternal Therapeutics Inc's reported EPS for the quarter
was a
loss of 20 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.6%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Oncternal Therapeutics Inc shares had fallen by 58.2% this
quarter and lost 67.2% so far this year.
    * The company reported a quarterly loss of $11.49 million.
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $1.90 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 09:52 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.20          -0.20          Met
 Dec. 31 2022      -0.21          -0.20          Beat
 Sep. 30 2022      -0.24          -0.21          Beat
 Jun. 30 2022      -0.23          -0.23          Met